Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

Unraveling the Mysteries of the Asthmatic Airway Epithelium.

Loukides S, Bakakos P.

Am J Respir Cell Mol Biol. 2018 Jul;59(1):9-10. doi: 10.1165/rcmb.2018-0040ED. No abstract available.

PMID:
29957048
2.

The self-reported prevalence and disease burden of asthma in Greece.

Kourlaba G, Bakakos P, Loukides S, Vellopoulou K, Solakidi A, Maniadakis N.

J Asthma. 2018 May 2:1-20. doi: 10.1080/02770903.2018.1471704. [Epub ahead of print]

PMID:
29718784
3.

Acrometastasis due to lung adenocarcinoma.

Apollonatou V, Loukides S, Papaioannou AI, Papiris S.

Adv Respir Med. 2018;86(2):97-100. doi: 10.5603/ARM.2018.0013.

4.

Falsely Elevated CA 15-3 Levels in Ovarian Sarcoidosis with Peritoneal Involvement and Ascites.

Tsiodras S, Gouloumi AR, Tsakiraki Z, Chrelias G, Chrelias C, Loukides S, Panayiotides I.

Case Rep Obstet Gynecol. 2018 Jan 22;2018:2039730. doi: 10.1155/2018/2039730. eCollection 2018.

5.

Serum osteopontin in patients with lung cancer and chronic obstructive pulmonary disease: does the co-existence make the difference?

Petta V, Loukides S, Kostikas K, Papaioannou AI, Papatheodorou G, Cholidou K, Tomos I, Papiris S, Koulouris NG, Bakakos P.

J Thorac Dis. 2018 Feb;10(2):740-748. doi: 10.21037/jtd.2018.01.45.

6.

An algorithmic approach for the treatment of severe uncontrolled asthma.

Zervas E, Samitas K, Papaioannou AI, Bakakos P, Loukides S, Gaga M.

ERJ Open Res. 2018 Mar 6;4(1). pii: 00125-2017. doi: 10.1183/23120541.00125-2017. eCollection 2018 Jan. Review.

7.

Serum Surfactant Protein Levels in Patients Admitted to the Hospital with Acute COPD Exacerbation.

Papaioannou AI, Konstantelou E, Papaporfyriou A, Bartziokas K, Spathis A, Bakakos P, Loukides S, Koulouris N, Papiris S, Kostikas K.

Lung. 2018 Apr;196(2):201-205. doi: 10.1007/s00408-018-0099-5. Epub 2018 Feb 14.

PMID:
29445934
8.

Targeted anti-IL-13 therapies in asthma: current data and future perspectives.

Ntontsi P, Papathanassiou E, Loukides S, Bakakos P, Hillas G.

Expert Opin Investig Drugs. 2018 Feb;27(2):179-186. doi: 10.1080/13543784.2018.1427729. Epub 2018 Jan 19. Review.

PMID:
29334288
9.

Ability of using different dry powder inhalers during COPD exacerbations.

Papaioannou AI, Herodotou Y, Tomos I, Apollonatou V, Verykokou G, Papathanasiou E, Manali ED, Loukides S, Papiris SA.

Pulm Pharmacol Ther. 2018 Feb;48:211-216. doi: 10.1016/j.pupt.2017.12.007. Epub 2017 Dec 19.

PMID:
29277688
10.

Exhaled breath temperature in optimally treated asthmatics: severity and underlying mechanisms.

Ntontsi P, Bakakos P, Papathanasiou E, Tsilogianni Z, Kostikas K, Hillas G, Papatheodorou G, Koulouris N, Papiris S, Loukides S.

J Breath Res. 2018 Feb 20;12(2):026013. doi: 10.1088/1752-7163/aa9d46.

PMID:
29176061
11.

Emphysematous Phenotype is Characterized by Low Blood Eosinophils: A Cross-Sectional Study.

Papaioannou AI, Kostikas K, Papaporfyriou A, Angelakis L, Papathanasiou E, Hillas G, Mazioti A, Bakakos P, Koulouris N, Papiris S, Loukides S.

COPD. 2017 Dec;14(6):635-640. doi: 10.1080/15412555.2017.1386644. Epub 2017 Nov 3.

PMID:
29099646
12.

The role of non-invasive modalities for assessing inflammation in patients with non-cystic fibrosis bronchiectasis.

Tsikrika S, Dimakou K, Papaioannou AI, Hillas G, Thanos L, Kostikas K, Loukides S, Papiris S, Koulouris N, Bakakos P.

Cytokine. 2017 Nov;99:281-286. doi: 10.1016/j.cyto.2017.08.005. Epub 2017 Aug 31.

PMID:
28863927
13.

High levels of IL-6 and IL-8 characterize early-on idiopathic pulmonary fibrosis acute exacerbations.

Papiris SA, Tomos IP, Karakatsani A, Spathis A, Korbila I, Analitis A, Kolilekas L, Kagouridis K, Loukides S, Karakitsos P, Manali ED.

Cytokine. 2018 Feb;102:168-172. doi: 10.1016/j.cyto.2017.08.019. Epub 2017 Aug 25.

PMID:
28847533
14.

Therapeutic effects of the combination of inhaled beta2-agonists and beta-blockers in COPD patients with cardiovascular disease.

Petta V, Perlikos F, Loukides S, Bakakos P, Chalkias A, Iacovidou N, Xanthos T, Tsekoura D, Hillas G.

Heart Fail Rev. 2017 Nov;22(6):753-763. doi: 10.1007/s10741-017-9646-z. Review.

PMID:
28840400
15.

Serum periostin in patients hospitalized for COPD exacerbations.

Konstantelou E, Papaioannou AI, Loukides S, Bartziokas K, Papaporfyriou A, Papatheodorou G, Bakakos P, Papiris S, Koulouris N, Kostikas K.

Cytokine. 2017 May;93:51-56. doi: 10.1016/j.cyto.2017.05.007. Epub 2017 May 13.

PMID:
28511944
16.

Decreased Serum Sirtuin-1 in COPD.

Yanagisawa S, Papaioannou AI, Papaporfyriou A, Baker JR, Vuppusetty C, Loukides S, Barnes PJ, Ito K.

Chest. 2017 Aug;152(2):343-352. doi: 10.1016/j.chest.2017.05.004. Epub 2017 May 12.

17.

A European Respiratory Society technical standard: exhaled biomarkers in lung disease.

Horváth I, Barnes PJ, Loukides S, Sterk PJ, Högman M, Olin AC, Amann A, Antus B, Baraldi E, Bikov A, Boots AW, Bos LD, Brinkman P, Bucca C, Carpagnano GE, Corradi M, Cristescu S, de Jongste JC, Dinh-Xuan AT, Dompeling E, Fens N, Fowler S, Hohlfeld JM, Holz O, Jöbsis Q, Van De Kant K, Knobel HH, Kostikas K, Lehtimäki L, Lundberg J, Montuschi P, Van Muylem A, Pennazza G, Reinhold P, Ricciardolo FLM, Rosias P, Santonico M, van der Schee MP, van Schooten FJ, Spanevello A, Tonia T, Vink TJ.

Eur Respir J. 2017 Apr 26;49(4). pii: 1600965. doi: 10.1183/13993003.00965-2016. Print 2017 Apr.

PMID:
28446552
18.

Predictors of response to therapy with omalizumab in patients with severe allergic asthma - a real life study.

Kallieri M, Papaioannou AI, Papathanasiou E, Ntontsi P, Papiris S, Loukides S.

Postgrad Med. 2017 Aug;129(6):598-604. doi: 10.1080/00325481.2017.1321945. Epub 2017 Apr 28.

PMID:
28427296
19.

Direct and Indirect Costs of Asthma Management in Greece: An Expert Panel Approach.

Souliotis K, Kousoulakou H, Hillas G, Bakakos P, Toumbis M, Loukides S, Vassilakopoulos T.

Front Public Health. 2017 Apr 5;5:67. doi: 10.3389/fpubh.2017.00067. eCollection 2017.

20.

Clinical, functional and inflammatory characteristics in patients with paucigranulocytic stable asthma: Comparison with different sputum phenotypes.

Ntontsi P, Loukides S, Bakakos P, Kostikas K, Papatheodorou G, Papathanassiou E, Hillas G, Koulouris N, Papiris S, Papaioannou AI.

Allergy. 2017 Nov;72(11):1761-1767. doi: 10.1111/all.13184. Epub 2017 May 11.

PMID:
28407269
21.

The association between serum periostin and a type 2 helper airway composite index in optimally treated asthmatics.

Konstantellou E, Loukides S, Ntontsi P, Papathanasiou E, Kostikas K, Paptheodorou G, Hillas G, Papiris S, Koulouris NG, Bakakos P.

J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):1129-1131.e3. doi: 10.1016/j.jaip.2017.03.005. Epub 2017 Apr 7. No abstract available.

PMID:
28396112
22.

Asthma phenotypes in children and stratified pharmacological treatment regimens.

Iordanidou M, Loukides S, Paraskakis E.

Expert Rev Clin Pharmacol. 2017 Mar;10(3):293-303. doi: 10.1080/17512433.2017.1271322. Epub 2016 Dec 20. Review.

PMID:
27936975
23.

How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?

Beeh KM, Burgel PR, Franssen FME, Lopez-Campos JL, Loukides S, Hurst JR, Fležar M, Ulrik CS, Di Marco F, Stolz D, Valipour A, Casserly B, Ställberg B, Kostikas K, Wedzicha JA.

Am J Respir Crit Care Med. 2017 Jul 15;196(2):139-149. doi: 10.1164/rccm.201609-1794CI. Review.

24.

Severe asthma: anti-IgE or anti-IL-5?

Papathanassiou E, Loukides S, Bakakos P.

Eur Clin Respir J. 2016 Nov 7;3:31813. doi: 10.3402/ecrj.v3.31813. eCollection 2016. Review.

25.

Activin A and follistatin in patients with asthma. Does severity make the difference?

Papaporfyriou A, Bakakos P, Kostikas K, Papatheodorou G, Hillas G, Trigidou R, Katafigiotis P, Koulouris NG, Papiris SA, Loukides S.

Respirology. 2017 Apr;22(3):473-479. doi: 10.1111/resp.12937. Epub 2016 Nov 2.

PMID:
27807906
26.

Sputum interleukin-13 as a biomarker for the evaluation of asthma control.

Tsilogianni Z, Hillas G, Bakakos P, Aggelakis L, Konstantellou E, Papaioannou AI, Papaporfyriou A, Papiris S, Koulouris N, Loukides S, Kostikas K.

Clin Exp Allergy. 2016 Nov;46(11):1498. doi: 10.1111/cea.12825. No abstract available.

PMID:
27790845
27.

Quantitative computed tomography: what does airway obstruction look-like?

Kallieri M, Papaioannou AI, Kostikas K, Bakakos P, Loukides S.

J Thorac Dis. 2016 Sep;8(9):E1044-E1046. No abstract available.

28.

Predictors of future exacerbation risk in patients with asthma.

Papaioannou AI, Kostikas K, Bakakos P, Papaporfyriou A, Konstantellou E, Hillas G, Papatheodorou G, Koulouris NG, Papiris S, Loukides S.

Postgrad Med. 2016 Sep;128(7):687-92. doi: 10.1080/00325481.2016.1220807. Epub 2016 Aug 17.

PMID:
27494758
29.

Serum Levels of Surfactant Proteins in Patients with Combined Pulmonary Fibrosis and Emphysema (CPFE).

Papaioannou AI, Kostikas K, Manali ED, Papadaki G, Roussou A, Spathis A, Mazioti A, Tomos I, Papanikolaou I, Loukides S, Chainis K, Karakitsos P, Griese M, Papiris S.

PLoS One. 2016 Jun 23;11(6):e0157789. doi: 10.1371/journal.pone.0157789. eCollection 2016.

30.

Biomarkers Guided Treatment Strategies in Adult Patients with Asthma: Ready for the Clinical Field?

Tsilogianni Z, Ntontsi P, Papaioannou AI, Bakakos P, Loukides S.

Arch Immunol Ther Exp (Warsz). 2017 Feb;65(1):1-9. doi: 10.1007/s00005-016-0407-9. Epub 2016 Jun 8. Review.

PMID:
27271573
31.

A Case of Organizing Pneumonia (OP) Associated with Pembrolizumab.

Fragkou P, Souli M, Theochari M, Kontopoulou C, Loukides S, Koumarianou A.

Drug Target Insights. 2016 May 22;10:9-12. doi: 10.4137/DTI.S31565. eCollection 2016.

32.

Sputum interleukin-13 as a biomarker for the evaluation of asthma control.

Tsilogianni Z, Hillas G, Bakakos P, Aggelakis L, Konstantellou E, Papaioannou AI, Papaporfyriou A, Papiris S, Koulouris N, Loukides S, Kostikas K.

Clin Exp Allergy. 2016 Jul;46(7):923-31. doi: 10.1111/cea.12729. Epub 2016 May 3. Erratum in: Clin Exp Allergy. 2016 Nov;46(11):1498.

PMID:
26990030
33.

Duration of Hospitalization and Lung Function Deterioration as Predictors of Future Chronic Obstructive Pulmonary Disease Exacerbations.

Papaioannou AI, Bartziokas K, Papiris S, Loukides S, Kostikas K.

Am J Respir Crit Care Med. 2016 Mar 15;193(6):698-700. doi: 10.1164/rccm.201511-2141LE. No abstract available.

PMID:
26977972
34.

Changes in BODE Quartiles After Pulmonary Rehabilitation Do Not Predict 2-Year Survival in Patients With COPD.

Kavoura P, Kostikas K, Tselebis A, Bratis D, Kosmas E, Alchanatis M, Koulouris NG, Bakakos P, Loukides S.

J Cardiopulm Rehabil Prev. 2016 Jan-Feb;36(1):62-7. doi: 10.1097/HCR.0000000000000157.

PMID:
26629865
35.

Smoking asthma phenotype: diagnostic and management challenges.

Bakakos P, Kostikas K, Loukides S.

Curr Opin Pulm Med. 2016 Jan;22(1):53-8. doi: 10.1097/MCP.0000000000000221. Review.

PMID:
26606078
36.

Biomarkers in the Management of Chronic Lung Disease.

Kostikas K, Loukides S, Bakakos P.

Curr Top Med Chem. 2016;16(14):1537-8. No abstract available.

PMID:
26510585
37.

Phenotyping and Endotyping Asthma Based on Biomarkers.

Perlikos F, Hillas G, Loukides S.

Curr Top Med Chem. 2016;16(14):1582-6. Review.

PMID:
26420366
38.

Persistent airflow obstruction in patients with asthma: Characteristics of a distinct clinical phenotype.

Konstantellou E, Papaioannou AI, Loukides S, Patentalakis G, Papaporfyriou A, Hillas G, Papiris S, Koulouris N, Bakakos P, Kostikas K.

Respir Med. 2015 Nov;109(11):1404-9. doi: 10.1016/j.rmed.2015.09.009. Epub 2015 Sep 21.

39.

The diverse roles of adiponectin in non-small-cell lung cancer: current data and future perspectives.

Boura P, Loukides S, Grapsa D, Achimastos A, Syrigos K.

Future Oncol. 2015;11(15):2193-203. doi: 10.2217/fon.15.96. Review.

PMID:
26235182
40.

Cardiovascular comorbidities in hospitalised COPD patients: a determinant of future risk?

Papaioannou AI, Bartziokas K, Loukides S, Tsikrika S, Karakontaki F, Haniotou A, Papiris S, Stolz D, Kostikas K.

Eur Respir J. 2015 Sep;46(3):846-9. doi: 10.1183/09031936.00237014. Epub 2015 Apr 16. No abstract available.

41.

Low interleukin (IL)-18 levels in sputum supernatants of patients with severe refractory asthma.

Rovina N, Dima E, Bakakos P, Tseliou E, Kontogianni K, Papiris S, Koutsoukou A, Koulouris NG, Loukides S.

Respir Med. 2015 May;109(5):580-7. doi: 10.1016/j.rmed.2015.03.002. Epub 2015 Mar 19.

42.

Sputum and BAL Clara cell secretory protein and surfactant protein D levels in asthma.

Emmanouil P, Loukides S, Kostikas K, Papatheodorou G, Papaporfyriou A, Hillas G, Vamvakaris I, Triggidou R, Katafigiotis P, Kokkini A, Papiris S, Koulouris N, Bakakos P.

Allergy. 2015 Jun;70(6):711-4. doi: 10.1111/all.12603. Epub 2015 Mar 18.

PMID:
25728058
43.

Angiopoietins 1 and 2 in sputum supernatant of optimally treated asthmatics: the effect of smoking.

Petta V, Bakakos P, Tseliou E, Kostikas K, Simoes DC, Konstantellou E, Hillas G, Koulouris NG, Papiris S, Loukides S.

Eur J Clin Invest. 2015 Jan;45(1):56-62. doi: 10.1111/eci.12379.

PMID:
25402718
44.

8-Isoprostane in exhaled breath condensate of patients with non-small cell lung cancer: the effect of chemotherapy.

Stathopoulos D, Loukides S, Syrigos K.

Anticancer Res. 2014 Sep;34(9):5143-5.

PMID:
25202105
45.

Exhaled breath condensate in acute and chronic heart failure: new insights into the role of lung injury and barrier dysfunction.

Pappas LK, Giannopoulos G, Loukides S, Gavrielatos G, Athanasopoulou E, Alexanian IP, Farmakis D, Korovesi I, Letsas KP, Parissis JT, Deftereos S, Pyrgakis VN, Kotanidou A, Kremastinos DT, Filippatos GS.

Am J Respir Crit Care Med. 2014 Aug 1;190(3):342-5. doi: 10.1164/rccm.201402-0272LE. No abstract available.

PMID:
25084262
46.

NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma.

Corradi M, Chrystyn H, Cosio BG, Pirozynski M, Loukides S, Louis R, Spinola M, Usmani OS.

Expert Opin Drug Deliv. 2014 Sep;11(9):1497-506. doi: 10.1517/17425247.2014.928282. Epub 2014 Jun 12. Review. Erratum in: Expert Opin Drug Deliv. 2014 Nov;11(11):1827.

47.

Increased levels of osteopontin in sputum supernatant in patients with COPD.

Papaporfyriou A, Loukides S, Kostikas K, Simoes DCM, Papatheodorou G, Konstantellou E, Hillas G, Papiris S, Koulouris N, Bakakos P.

Chest. 2014 Oct;146(4):951-958. doi: 10.1378/chest.13-2440.

PMID:
24902063
48.

Collateral damage: depressive symptoms in the partners of COPD patients.

Papaioannou AI, Tsikrika S, Bartziokas K, Karakontaki F, Kastanakis E, Diamantea F, Haniotou A, Papiris S, Polychronopoulos V, Loukides S, Kostikas K.

Lung. 2014 Aug;192(4):519-24. doi: 10.1007/s00408-014-9595-4. Epub 2014 May 11.

PMID:
24816968
49.

Serum angiopoietin-2 and CRP levels during COPD exacerbations.

Nikolakopoulou S, Hillas G, Perrea D, Tentolouris N, Loukides S, Kostikas K, Simoes D, Georgakopoulou E, Vogiatzakis E, Veldekis D, Bakakos P.

COPD. 2014 Feb;11(1):46-51. doi: 10.3109/15412555.2013.829436. Epub 2013 Oct 8.

PMID:
24102428
50.

Biomarkers in COPD: is mortality the Holy Grail?

Kostikas K, Loukides S, Bakakos P.

COPD. 2013 Oct;10(5):557-9. doi: 10.3109/15412555.2013.832092. No abstract available.

PMID:
24040907

Supplemental Content

Loading ...
Support Center